Reagent for detecting SNP sites of P53 genes and application of reagent

Abstract

The invention discloses a reagent for detecting SNP sites of P53 genes and application of the reagent. The reagent comprises a reagent which can be used for detecting genotype of rs17881013 site in the P53 genes. A patient is subjected to genetic typing, correlation between the SNP sites of P53 genes and gefitinib on treatment response of advanced non-small cell lung cancer is analyzed, and the treatment response of a patient suffering from the advanced non-small cell lung cancer on the gefitinib can be judged according to the genotype of the rs17881013 site. The development of the reagent provides a reliable and sensitive mode for determining a treatment plan of the patient suffering from the advanced non-small cell lung cancer.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a reagent for detecting the SNP site of P53 gene and its use in preparing a kit for judging the responsiveness of advanced non-small cell lung cancer patients to gefitinib treatment. Background technique [0002] Lung cancer is one of the most common malignant tumors with the highest mortality rate, and its morbidity and mortality are still increasing year by year. Among them, non-small cell lung cancer (NSCLC) accounts for more than 80% of the whole lung cancer, and most of the patients are already in advanced stage when they are diagnosed. Chemotherapy used to be the most important treatment for advanced non-small cell lung cancer, but even with the best chemotherapy regimen, the total effective rate of current treatment is less than 50%, and the 1-year survival rate is only about 40%. [0003] The emergence of targeted therapy drugs has changed the current treatment status of non-sma...

AI Technical Summary

Problems solved by technology

Chemotherapy used to be the most important treatment for advanced non-small cell lung cancer, but even with the best chemotherapy regimen, the total effective rate of current treatment is less than 50%, and the 1-year survival rate is only about 40%

However, EGFR gene mutation, as a biomarker for predicting the efficacy of gefitinib, has certain shortcomings: ①The detection of mutation requires tumor tissue, and most lung cancers are already in the advanced stage when they are first diagnosed, and they lose the opportunity to obtain tumor samples through surgery. It is possible for a small number of patients to obtain biopsy specimens, and it is also difficult to perform mutation detection due to the limited detection rate and the limited amount of biopsy specimens. Currently, the proportion of patients who can meet the requirements of mutation detection clinically is less than 20% (about 17% in ISEL research). %); ②Gene mutations are affected by tumor heterogeneity. Tumor samples obtained from the same patient at different sites or at different stages of the disease may have different mutation detection results, so the detected results may not represent the characteristics of the whole body and the whole tumor ; ③The process of mutation detection is complicated, the requirements for instruments and equipment are high, it is difficult for general laboratories to carry out, and the detection cost is also high, which affects its wide clinical application

Images